• Sana set to file an IND application for SC451, a hypoimmune stem cell-derived islet therapy for type 1 diabetes.
• Phase 1/2 trial planned as early as this year, positioning SC451 as a potential one-time treatment.
• Program goal targets long-term normal blood glucose without insulin therapy or immunosuppression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.